Sai Life Sciences Shares Listed at Premium of ~20% on BSE

On December 18, 2024, Sai Life Sciences share price made a successful debut on Dalal Street at a notable premium. Sai Life Sciences shares were listed at ₹660 on the Bombay Stock Exchange (BSE), reflecting a premium of ₹111 or 20.2% over its issue price of ₹549. On the National Stock Exchange (NSE), it opened at ₹650, a premium of ₹101 or 18.3% against the issue price.

Overview of the IPO

Sai Life Sciences IPO raised a total of ₹3,042.62 crore, comprising both a fresh issue and an offer for sale (OFS) of equity shares. The IPO was offered in a price band of ₹522 – ₹549, with a minimum lot size of 27 shares. The subscription period for the IPO lasted from Wednesday, December 11, 2024, to Friday, December 13, 2024, and was oversubscribed by 10.26 times.

Subscription Details

The IPO saw significant demand from various investor categories:

• Qualified Institutional Buyers (QIBs) showed the highest demand, subscribing 30.90 times their reserved quota.
• Non-Institutional Investors (NIIs) subscribed 4.92 times their allotted share.
• Retail Individual Investors (RIIs) subscribed 1.37 times their share allocation.

Use of IPO Proceeds

Sai Life Sciences plans to utilise the proceeds from the fresh issue for:

1. Repayment or prepayment (in part or full) of outstanding borrowings.
2. General corporate purposes.

About Sai Life Sciences Limited

Founded in January 1999, Sai Life Sciences specialises in the research, development, and manufacturing of small-molecule new chemical entities. The company provides contract research (CRO) and contract development and manufacturing (CDMO) services to global pharmaceutical and biotech companies.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.